Formato Vancouver:
Jiménez C, González E, Marqués M, Galeano C, Andrés A, Calvo N, Pascual J. Impacto de darbepoetina alfa en el manejo de la anemia precoz postrasplante renal: estudio retrospectivo exploratorio. Nefrologia. 2013 Jan 18;33(1):107-15.

PMID: 23364633

Contiene 32 referencias

Background and objectives: The use of darbepoetin alfa in the first week of post-renal transplant (RT). Methods: Retrospective observational study carried out in four hospitals, which included all adult patients that underwent RT for 9 months with haemoglobin data during the first 6 months of post-transplant (n = 129). Darbepoetina alfa was administered in accordance with the clinical practice. Results: darbepoetin alfa was administered in the first week to 60 individuals (46.5%), who had a mean baseline Hb (+/- standard deviation) of 12.7g/dl +/- 1.6g/dl. Anaemia incidence (Hb < 11g/dl) during the first month was higher in patients who did not receive darbepoetin alfa (40.6% vs. 25.0% in patients treated with darbepoetin alfa, P=.045). No anaemia incidence differences were observed during months +2 to +6. There was a tendency towards transfusion decrease in patients who received darbepoetin alfa (13.3% vs. 20.3%, P=.295). Renal recovery time was similar but in the subgroup which received grafts from donors with asystole there was a tendency towards a faster recovery with darbepoetin alfa (15.1 +/- 7.7 vs. 20.1 +/- 8.8 days, P=.157). The creatinine clearance rate at 3 and 6 months was similar. Fourteen patients (10.9%) suffered from cardiovascular events with no relation to darbepoetin alfa (P=.772). Conclusions: Administering darbepoetin alfa in the first week following renal transplant reduces anaemia incidence during the first month without increase cardiovascular events.